Doximity, Inc.DOCSNYSE
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank33
3Y CAGR-31.6%
5Y CAGR-5.6%
Studio
Year-over-Year Change

Year-over-year research & development expense growth

3Y CAGR
-31.6%/yr
Annual compound
5Y CAGR
-5.6%/yr
Recent deceleration
Percentile
P33
Within normal range
vs 5Y Ago
0.8x
Contraction
Streak
1 yr
Consecutive growthRecovering
PeriodValue
202513.48%
20242.24%
202328.61%
202242.11%
202135.26%
202017.95%
20190.00%